GLP-1-SM

GLP-1-SM is our catalog designation for research-grade semaglutide, a synthetic 31-amino-acid peptide supplied as a lyophilized powder for laboratory research use only. Every lot is independently assayed by Janoshik Analytical and the Certificate of Analysis is published before the lot is listed.

Compound overview

Semaglutide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike dual or triple incretin agonists, it engages a single receptor target, which is precisely why it appears so often in the literature as a reference compound: it isolates GLP-1 receptor signaling without confounding input from GIP or glucagon receptor activity.

The sequence is derived from native human GLP-1 with three key modifications. Alanine at position 8 is substituted with alpha-aminoisobutyric acid, conferring resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. Lysine at position 34 is replaced with arginine. A C18 fatty diacid chain is conjugated to lysine at position 26 through a gamma-glutamyl and dual-OEG linker, driving reversible albumin binding and substantially extending circulating half-life in published pharmacokinetic models.

Research context

Semaglutide is used extensively as a tool compound in incretin receptor pharmacology. Researchers investigating GLP-1 receptor signaling commonly examine cAMP accumulation, beta-arrestin recruitment, receptor internalization and recycling kinetics, and biased agonism at the GLP-1 receptor. Because it is a single-target agonist with a well-characterized structure, it serves as the standard comparator when evaluating newer multi-receptor compounds.

For a structural and pharmacological comparison against dual-agonist chemistry, see our article on tirzepatide and dual GIP/GLP-1 receptor agonism, and our overview of semaglutide and GLP-1 receptor signaling.

This material is supplied strictly as a research chemical for qualified investigators working in a controlled laboratory setting. It is not a drug, not a dietary supplement, and is not intended for diagnostic, therapeutic, or human use of any kind.

Analytical verification

Every lot is tested by Janoshik Analytical, an independent third-party laboratory, before it is offered for sale. Testing covers identity and purity by HPLC, with mass spectrometry confirming molecular weight against the expected value for the semaglutide sequence.

The lot number on your vial label corresponds to a specific Certificate of Analysis in our COA Library. We publish the complete report rather than a headline purity figure, so the chromatogram and its integration are available for your own review. Our guide on how to actually read a Janoshik COA explains which sections matter and where misleading reports typically fall apart.

Specifications

• Compound: Semaglutide (catalog designation GLP-1-SM)
• Form: Lyophilized powder, sealed vial
• Molecular formula: C187H291N45O59
• Molecular weight: approximately 4113.6 g/mol
• Receptor target: GLP-1 receptor (selective agonist)
• Purity: See the published COA for the specific lot
• Testing: HPLC and MS by Janoshik Analytical
• Available sizes: 10mg per vial

Handling and storage

Store lyophilized material sealed and protected from light. Short-term storage at 2 to 8 degrees Celsius is appropriate for vials in active use; long-term storage at -20 degrees Celsius or below preserves stability over extended periods. Allow sealed vials to reach room temperature before opening, since condensation introduces moisture that accelerates degradation of lyophilized peptide.

Repeated freeze-thaw cycling is the most common avoidable source of degradation in laboratory handling. Aliquoting reconstituted material into single-use volumes prevents the full quantity from undergoing repeated temperature transitions. Bacteriostatic water is stocked for laboratories that require reconstitution diluent.

For laboratory research use only. Not for human or veterinary consumption. Not for diagnostic or therapeutic use.